371 related articles for article (PubMed ID: 19625624)
1. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
Guo D; Hildebrandt IJ; Prins RM; Soto H; Mazzotta MM; Dang J; Czernin J; Shyy JY; Watson AD; Phelps M; Radu CG; Cloughesy TF; Mischel PS
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12932-7. PubMed ID: 19625624
[TBL] [Abstract][Full Text] [Related]
2. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
3. Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.
Al-Moujahed A; Nicolaou F; Brodowska K; Papakostas TD; Marmalidou A; Ksander BR; Miller JW; Gragoudas E; Vavvas DG
Invest Ophthalmol Vis Sci; 2014 Apr; 55(7):4175-85. PubMed ID: 24781943
[TBL] [Abstract][Full Text] [Related]
4. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
5. AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.
Su CC; Hsieh KL; Liu PL; Yeh HC; Huang SP; Fang SH; Cheng WC; Huang KH; Chiu FY; Lin IL; Huang MY; Li CY
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987073
[TBL] [Abstract][Full Text] [Related]
6. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
Exp Cell Res; 2007 Oct; 313(16):3592-603. PubMed ID: 17669398
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
8. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway.
Kimura N; Tokunaga C; Dalal S; Richardson C; Yoshino K; Hara K; Kemp BE; Witters LA; Mimura O; Yonezawa K
Genes Cells; 2003 Jan; 8(1):65-79. PubMed ID: 12558800
[TBL] [Abstract][Full Text] [Related]
9. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase.
Rattan R; Giri S; Singh AK; Singh I
J Biol Chem; 2005 Nov; 280(47):39582-93. PubMed ID: 16176927
[TBL] [Abstract][Full Text] [Related]
11. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases.
Zajkowicz A; Rusin M
Mech Ageing Dev; 2011; 132(11-12):543-51. PubMed ID: 21945951
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
13. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.
Bolster DR; Crozier SJ; Kimball SR; Jefferson LS
J Biol Chem; 2002 Jul; 277(27):23977-80. PubMed ID: 11997383
[TBL] [Abstract][Full Text] [Related]
14. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.
Agarwal S; Bell CM; Rothbart SB; Moran RG
J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395
[TBL] [Abstract][Full Text] [Related]
15. Role of adenosine 5'-monophosphate-activated protein kinase subunits in skeletal muscle mammalian target of rapamycin signaling.
Deshmukh AS; Treebak JT; Long YC; Viollet B; Wojtaszewski JF; Zierath JR
Mol Endocrinol; 2008 May; 22(5):1105-12. PubMed ID: 18276828
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of cardiomyogenesis of embryonic stem cells by nitric oxide downstream of AMP-activated protein kinase and mTOR signaling pathways.
Padmasekar M; Sharifpanah F; Finkensieper A; Wartenberg M; Sauer H
Stem Cells Dev; 2011 Dec; 20(12):2163-75. PubMed ID: 21470048
[TBL] [Abstract][Full Text] [Related]
17. AICAR prolongs corneal allograft survival via the AMPK-mTOR signaling pathway in mice.
Jiang L; Liu T; Xie L; Ouyang C; Ji J; Huang T
Biomed Pharmacother; 2019 May; 113():108558. PubMed ID: 30856534
[TBL] [Abstract][Full Text] [Related]
18. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes.
Tong JF; Yan X; Zhu MJ; Du M
J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604
[TBL] [Abstract][Full Text] [Related]
19. AICAR positively regulate glycogen synthase activity and LDL receptor expression through Raf-1/MEK/p42/44MAPK/p90RSK/GSK-3 signaling cascade.
Wang HM; Mehta S; Bansode R; Huang W; Mehta KD
Biochem Pharmacol; 2008 Jan; 75(2):457-67. PubMed ID: 17945190
[TBL] [Abstract][Full Text] [Related]
20. AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions.
Thomson DM; Fick CA; Gordon SE
J Appl Physiol (1985); 2008 Mar; 104(3):625-32. PubMed ID: 18187610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
